On Monday, Arcellx earned an upgrade to its Relative Strength (RS) Rating, from 68 to 77.
How To Invest In Stocks In Both Bull And Bear Markets
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the market's biggest winners often have an RS Rating north of 80 as they launch their largest price moves. See if Arcellx can continue to show renewed price strength and hit that benchmark.
Arcellx is not currently near a potential buy zone. See if the stock goes on to build a base that could spark a new run.
The company posted 0% EPS growth in the latest quarterly report. Sales rose -72%.
Arcellx holds the No. 349 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
